Drug Profile
BI 691751
Alternative Names: BI-691751Latest Information Update: 26 Apr 2016
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Vascular disorder therapies
- Mechanism of Action Leukotriene A4 hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 01 Aug 2014 Boehringer Ingelheim terminates a phase I trial in Healthy male volunteers in Germany (NCT02148107)
- 01 May 2014 Boehringer Ingelheim completes a phase I trial in Healthy volunteers in Germany (NCT02044393)
- 01 May 2014 Boehringer Ingelheim completes a phase I trial in Healthy Asian male volunteers in South Korea (NCT02057835)